Perillyl Alcohol: Applications in Oncology

Alternative Medicine Review

Volumn 3, Issue 6, 1998, Pages 448-457

  Belanger, James T ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PERILLYL ALCOHOL; TERPENE;

ANIMAL; HUMAN; NEOPLASM; PHASE 1 CLINICAL TRIAL; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I; HUMANS; MONOTERPENES; NEOPLASMS; TERPENES;

EID: 0032254146     PISSN: 10895159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Tyler V. Pharmacognosy, 9th ed. Philadelphia, PA: Lea & Febiger; 1988:107.
2. Kelloff GJ, Boone CW, Crowell JA, et al. New agents for cancer chemoprevention. J Cellular Biochem 1996;26S:1-28.
3. Stark JM, Burke YD, McKinzie JH, et al. Chemotherapy of pancreatic cancer with the monoterpene perillyl alcohol. Cancer Lett 1995;96:15-21.
4. Stayrook KR, McKinzie JH, Burke YD, et al. Induction of the apoptosis-promoting protein Bak by perillyl alcohol in pancreatic ductal adenocarcinoma relative to untransformed ductal epithelial cells. Carcinogenesis 1997;18:1655-1658.
5. Haag JD, Gould MN. Mammary carcinoma regression induced by perillyl alcohol, a hydroxylated analog of limonene. Cancer Chemother Pharmacol 1994;34:477-483.
6. Mills JJ, Chari RS, Boyer U, et al. Induction of apoptosis in liver tumors by the monoterpene perillyl alcohol. Cancer Res 1995;55:979-983.
7. Shi W, Gould MN. Induction of differentiation in neuro-2A cells by the monoterpene perillyl alcohol. Cancer Lett 1995;95:1-6.
8. Jeffers L. The effect of perillyl alcohol on the proliferation of human prostatic cell lines. Proc Am Assoc Cancer Res 1995;36:303.
9. Qi C, Park JH, Gibbs TC, et al. Lysophosphatidic acid stimulates phospholipase D activity and cell proliferation in PC-3 human prostate cancer cells. J Cell Physiol 1998;174:261-272.
10. Schulz S, Reinhold D, Schmidt H, et al. Perillic acid inhibits Ras/MAP kinase-driven IL-2 production in human T lymphocytes. Biochem Biophys Res Commun 1997;241:720-725.
11. Reddy BS, Wang CX, Samaha H, et al. Chemoprevention of colon carcinogenesis by dietary perillyl alcohol. Cancer Res 1997;57:420-425.
12. Maltzman TH, Christou M, Gould MN, Jeffcoat CR. Effects of monoterpenoids on in vivo DMBA-DNA adduct formation and on Phase I hepatic metabolizing enzymes. Carcinogenesis 1991;12:2081 -2087.
13. Elegbede JA, Maltzman TH, Elson CE, Gould MN. Effects of anticarcinogenic monoterpenes on Phase II hepatic metabolizing enzymes. Carcinogenesis 1993;14:1221-1223.
14. Broitman SA, Wilkinson J 4th, Gerda S, Branch SK. Effects of monoterpenes and mevinolin on murine colon tumor CT-26 in vitro and its hepatic "metastases" in vivo. Adv Exp Med Biol 1996;401:111 -130.
15. Barthelman M, Chen W, Gensler HL, et al. Inhibitory effects of perillyl alcohol on UVB-induced murine skin cancer and AP-1 transactivation. Cancer Res 1998;58:711-716.
16. He L, Mo H, Hadisusilo S, et al. Isoprenoids suppress the growth of murine B16 melanomas in vitro and in vivo. J Nutr 1997;127:668-674.
17. Lantry LE, Zhang Z, Gao F, et al. Chemopreventive effect of perillyl alcohol on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induced tumorigenesis in (C3H/HeJ X A/J) F1 mouse lung. J Cell Biochem Suppl 1997;27:20-25.
18. Ripple GH, Gould MN, Stewart JA, et al. Phase I clinical trial of perillyl alcohol administered daily. Clin Cancer Res 1998;4:1159-1164.
19. Ren Z, Gould MN. Modulation of small G protein isoprenylation by anticancer monoterpenes in in situ mammary gland epithelial cells. Carcinogenesis 1998;19:827-832.
20. Crane FL, Sun IL, Crowe RA, et al. Coenzyme Q10, plasma membrane oxidase and growth control. Mol Aspects Med 1994;15S: 1-11.
21. Lockwood K, Moesgaard S, Yamamoto T, Folkers K. Progress on therapy of breast cancer with vitamin Q10 and the regression of metastases. Biochem Biophys Res Commun 1995;212:172-177.
22. Lockwood K. Partial and complete regression of breast cancer in patients in relation to dosage of coenzyme Q10. Biochem Biophys Res Commun 1994;199:1504-1508.
23. Jirtle RL, Gould MN. Increased mannose 6-phosphate/insulin-like growth factor II receptor and transforming growth factor beta 1 levels during monoterpene-induced regression of mammary tumors. Cancer Res 1993;53:3849-3852.
24. Yu W, Heim K, Qian M, et al. Evidence for role of transforming growth factor-beta in RRR-alpha-tocopheryl succinate-induced apoptosis of human MDA-MB-435 breast cancer cells. Nutr Cancer 1997;27:267-278.
25. Shi W, Gould MN. The anticancer monoterpene perillyl alcohol causes a decrease in cellular cyclin D1 levels contributing to an early G1 arrest in mammary cells. Proc Am Assoc Cancer Res 1997;38:263.
26. Tao L, Pereira MA. Quantification of carvone, cineole, perillaldehyde, perillyl alcohol and sobrerol by isocratic high-performance liquid chromatography. J Chromatogr A 1998;793:71-76.
27. Ikechukwu EE, Phillips LR, Wolfe TL, Esmail TS. Analysis of perillic acid in plasma by reversed-phase high performance liquid chromatography with ultraviolet detection. J Chromatogr B 1997;688:354-358.
28. Williams AC, Barry BW. Terpenes and the lipid-protein-partitioning theory of skin penetration enhancement. Pharm Res 1991;8:17-24.
29. National Cancer Institute, Division of Cancer Prevention and Control, Chemoprevention Branch, and Agent Development Committee. Clinical development plan: L-perillyl alcohol. J Cell Biochem 1996;26:137-148.
30. S. Distasio, RN, Yale Cancer Center, personal communication, August 14, 1997.
31. Hudes GR, Szarka C, Adams A, et al. Phase I trial of perillyl alcohol in patients with refractory solid tumors. Fox Chase Cancer Center, Philadelphia, PA. (unpublished)